

Phone: 608-266-2112 Web: http://dsps.wi.gov Email: dsps@wisconsin.gov

Tony Evers, Governor Dawn B. Crim, Secretary

CONTROLLED SUBSTANCES BOARD VIRTUAL/TELECONFERENCE Virtual, 4822 Madison Yards Way, Madison Contact: Adam Barr (608) 266-2112 November 12, 2021

The following agenda describes the issues that the Board plans to consider at the meeting. At the time of the meeting, items may be removed from the agenda. Please consult the meeting minutes for a description of the actions and deliberations of the Board.

AGENDA

9:30 A.M. OR IMMEDIATELY FOLLOWING THE REFERRAL CRITERIA WORK GROUP MEETING

OPEN SESSION – CALL TO ORDER – ROLL CALL

A. Adoption of Agenda (1-3)

B. 9:30 A.M. ANNUAL HEARING WITH LAW ENFORCEMENT LEADERS, AGENCIES, AND PROSECUTORS – Discussion and Consideration (4-5)

1) Introduction

- a. Overview of Executive Order (EO) 228
- b. Background on the Wisconsin Controlled Substances Board
- 2) Overview of Scheduling Processes Wisconsin Statutes § 961.11 (6-10)
- 3) Receive Testimony Discussion Regarding Drug Trends
 - a. Presentations from Special Guests
 - b. Presentation from the Wisconsin State Crime Lab Bureau
 - c. Testimony from the Law Enforcement Community
 - d. Open Discussion
- C. Approval of Minutes September 10, 2021 (11-12)
- D. Reminders: Conflicts of Interests, Scheduling Concerns
- E. Introductions, Announcements and Recognition

F. Administrative Matters – Discussion and Consideration

- 1) Department, Staff, and Board Updates
- 2) Board Members Term Expiration Dates
 - a. Barman, Subhadeep 5/1/2019
 - b. Bellay, Yvonne
 - c. Bloom, Alan 5/1/2020
 - d. Englebert, Doug
 - e. Ferguson, Kris
 - f. Kallio, Peter

- g. Kaske, Herbert
- h. Koresch, Sandy
- i. Weitekamp, John

Revised Guidance Regarding the Designation of Gabapentin as a Monitored Prescription Drug (13-15) – *Added via Addendum*

G. Administrative Rule Matters – Discussion and Consideration (16-27)

- 1) Preliminary Rule Draft:
 - a. CSB 2.78, Relating to Scheduling Crotonyl Fentanyl
 - b. CSB 2.79, Relating to Scheduling Remimazolam
 - c. CSB 2.81, Relating to Scheduling Brorphine
- 2) Pending and Possible Rulemaking Projects

H. Prescription Drug Monitoring Program (PDMP) Update – Discussion and Consideration (28-35)

- 1) WI ePDMP Operations
 - a. Q3 2021 Report
 - b. Recent and Upcoming Releases
 - c. Status of Grant Projects:
 - 1. FY 2020 Harold Rogers Prescription Drug Monitoring Program
 - a. Buprenorphine Naïve Alert
 - 2. Overdose Data Exchange Project
 - 3. Buprenorphine Exclusion Project
 - d. Interstate Data Sharing
 - e. EHR Integration Status
- 2) WI ePDMP Outreach
- I. COVID-19 Discussion and Consideration

J. Board Member Reports – Discussion and Consideration

- 1) Medical Examining Board
- 2) Dentistry Examining Board
- 3) Board of Nursing
- 4) Pharmacy Examining Board
- K. Liaison Reports

L. Report from the Referral Criteria Work Group – Discussion and Consideration

- M. Deliberation on Special Use Authorizations Discussion and Consideration
- N. Discussion and Consideration of Items Received After Preparation of the Agenda
 - 1) Introductions, Announcements, and Recognition
 - 2) Administrative Matters
 - 3) Election of Officers
 - 4) Appointment of Liaisons and Alternates
 - 5) Delegation of Authorities
 - 6) Informational Items
 - 7) Division of Legal Services and Compliance (DLSC) Matters
 - 8) Education and Examination Matters
 - 9) Credentialing Matters

- 10) Practice Matters
- 11) Legislative and Administrative Rule Matters
- 12) Liaison Reports
- 13) Appearances from Requests Received or Renewed
- 14) Speaking Engagements, Travel, or Public Relations Requests, and Reports
- 15) Consulting with Legal Counsel

O. Public Comments

CONVENE TO CLOSED SESSION to deliberate on cases following hearing (s. 19.85(1)(a), Stats.); to consider licensure or certification of individuals (s. 19.85(1)(b), Stats.); to consider individual histories or disciplinary data (s. 19.85(1)(f), Stats.); and to confer with legal counsel (s. 19.85(1)(g), Stats.).

- P. Deliberation on Special Use Authorizations Discussion and Consideration
- **Q.** Consulting with Legal Counsel

RECONVENE TO OPEN SESSION IMMEDIATELY FOLLOWING CLOSED SESSION

- **R.** Vote on Items Considered or Deliberated Upon in Closed Session if Voting is Appropriate
- S. Open Session Items Noticed Above Not Completed in the Initial Open Session

ADJOURNMENT

NEXT MEETING: JANUARY 14, 2022

MEETINGS AND HEARINGS ARE OPEN TO THE PUBLIC, AND MAY BE CANCELLED WITHOUT NOTICE.

Times listed for meeting items are approximate and depend on the length of discussion and voting. All meetings are held at 4822 Madison Yards Way, Madison, Wisconsin, unless otherwise noted. To confirm a meeting or to request a complete copy of the board's agenda, please call the listed contact person. The board may also consider materials or items filed after the transmission of this notice. Times listed for the commencement of disciplinary hearings may be changed by the examiner for the convenience of the parties. Requests for interpreters for the deaf or hard of hearing, or other accommodations, are considered upon request by contacting the Affirmative Action Officer, 608-266-2112, or the Meeting Staff at 608-266-5439.


State of Wisconsin Department of Safety & Professional Services

1) Name and title of person submitting the request: 2) Date when request submitted:				
Adam Barr, Executive D	•	11/2/21		
		Items will be considered late if submitted after 12:00 p.m. on the deadline		
		date which is 8 business days before the meeting		
3) Name of Board, Committee, Council, Sections:				
Controlled Substances				
4) Meeting Date:	5) Attachments:	6) How should the item be titled on the agenda page?		
11/12/21	🗌 Yes	9:30 A.M. ANNUAL HEARING WITH LAW ENFORCEMENT LEADERS, AGENCIES, AND PROSECUTORS – Discussion and Consideration		
	🖂 No	1. Introduction		
		a. Overview of Executive Order (EO) 228		
		b. Background on the Wisconsin Controlled Substances		
		2. Overview of Scheduling Processes – Wisconsin Statutes		
		§ 961.11		
		3. Receive Testimony Discussion Regarding Drug Trends		
		a. Presentations from Special Guests		
		b. Presentation from the Wisconsin State Crime Lab		
		Bureau c. Testimony from the Law Enforcement Community		
		d. Open Discussion		
7) Place Item in:	8) Is an appearan	nce before the Board being 9) Name of Case Advisor(s), if required:		
, 	<i>i</i>	ves, please complete		
Open Session	Appearance Req	uest for Non-DSPS Staff)		
Closed Session	☐ Yes			
10) Describe the issue a	Ind action that should be add	Idressed:		
.,				

AGENDA REQUEST FORM

State of Wisconsin Department of Safety & Professional Services

11)	Authorization
Signature of person making this request	Date
Supervisor (if required)	Date
Executive Director signature (indicates approval	I to add post agenda deadline item to agenda) Date



CONTROLLED SUBSTANCE SCHEDULING OVERVIEW

Nilajah Hardin Administrative Rules Coordinator, DSPS

- Process Completed by the Controlled Substances Board
- ► Drug with the potential for abuse designated as a controlled substance in WI
- Analogs of a substance can also be scheduled

WHAT IS SCHEDULING?


- ► Legality of possessing a drug
- ► How a drug's distribution is penalized
- ► Ability of non-physician healthcare providers to prescribe


WHAT CAN BE IMPACTED BY SCHEDULING?

3

Schedule II	Methamphetamine, Cocaine, Opiates	
Schedule III	Barbiturates, Anabolic Steroids	
Schedule IV	Benzodiazepines, Ephedrine, Tramadol	
-		
Schedule V	Pseudoephedrine	

7











- Potential for abuse
- Scientific evidence of pharmacological effect
- Current scientific knowledge on the substance
- History and current pattern of abuse
- Scope, duration and significance of abuse
- Risk to public health
- Potential to produce psychological or physical dependence
- Whether the substance is an immediate precursor of an already scheduled substance

STANDARD SCHEDULING

- ► 3 Factors
 - History and current pattern of abuse for the drug
 - Scope, duration, and significance of abuse
 - ▶ Risk to public health
- Requested by a district attorney prosecuting a case
- Emergency Rules Process drug scheduled for 1 year
- Permanent Rules Process must be in place before emergency rule expires

EMERGENCY SCHEDULING

9

- Affirmative Action Process
 - DEA schedules a drug and it's published in the Federal Register
 - Board must wait 30 days from DEA publication before scheduling
 - Board approves and publishes an Affirmative Action Order
 - Affirmative Action Order schedules drug into the same schedule under WI
 - Affirmative Action Order is effective upon publication until permanent rule goes into effect
 - Board then follows Permanent Rules Process

SCHEDULING BASED ON FEDERAL ACTION

VIRTUAL/TELECONFERENCE CONTROLLED SUBSTANCES BOARD MEETING MINUTES SEPTEMBER 10, 2021

- **PRESENT:** Yvonne Bellay, Alan Bloom, Doug Englebert, Sandy Koresch, Michael Parish, Emily Zentz
- EXCUSED: Subhadeep Barman, Kris Ferguson, Peter Kallio, Herbert Kaske, John Weitekamp
- **STAFF:** Adam Barr, Executive Director; Jameson Whitney, Legal Counsel; Nilajah Hardin, Administrative Rules Coordinator; Katlin Schwartz, Bureau Assistant; Megan Glaeser, Bureau Assistant; and other DSPS Staff

(Dr. Michael Parish served as the representative for the Medical Examining Board at this meeting.)

(Emily Zentz served as the representative for the Board of Nursing at this meeting.)

CALL TO ORDER

Doug Englebert, Chairperson, called the meeting to order at 9:32 a.m. A quorum was confirmed with six (6) members present.

ADOPTION OF AGENDA

MOTION: Alan Bloom moved, seconded by Yvonne Bellay, to adopt the Agenda as published. Motion carried unanimously.

APPROVAL OF MINUTES OF JULY 9, 2021

MOTION: Sandy Koresch moved, seconded by Alan Bloom, to adopt the Minutes of July 9, 2021 as published. Motion carried unanimously.

ADMINISTRATIVE RULE MATTERS

Preliminary Rule Draft

CSB 2.80, Relating to Scheduling Oliceridine

MOTION: Alan Bloom moved, seconded by Michael Parish, to approve the preliminary rule draft of CSB 2.80, relating to scheduling Oliceridine, for posting for economic impact comments and submission to the Clearinghouse. Motion carried unanimously.

Virtual/Teleconference Controlled Substances Board Meeting Minutes September 10, 2021 Page 1 of 2

Scope Statement

- **MOTION:** Michael Parish moved, seconded by Sandy Koresch, to approve the following Scope Statements for submission to the Department of Administration and Governor's Office and for publication:
 - 1. CSB 2.82, Relating to Scheduling Serdexmethylphenidate
 - 2. CSB 2.83, Relating to Scheduling Ten (10) Fentanyl Related Substances
 - 3. CSB 2.84, Relating to Scheduling Alfaxalone
 - 4. CSB 2.85, Relating to Excluding 6-beta-Nalterxol
 - 5. CSB 2.86, Relating to Scheduling Fospropofol
 - 6. CSB 2.87, Relating to Scheduling Embutramide
 - 7. CSB 2.88, Relating to Scheduling Lacosamide
 - 8. CSB 2.89, Relating to Scheduling Perampanel
 - 9. CSB 2.90, Relating to Transferring 1-phenylcyclohexylamine and 1piperidinocyclohexanecarbonitrile, Immediate Precursors to Phencyclidine, Also Known as PCP

Additionally, the Board authorizes the Chairperson to approve these Scope Statements for implementation no less than 10 days after publication. If the Board is directed to hold a preliminary public hearing on these Scope Statements, the Chairperson is authorized to approve the required notices of hearing. Motion carried unanimously.

Affirmative Action Order

CSB 2.91, Relating to Scheduling 4,4'-Dimethylaminorex

MOTION: Yvonne Bellay moved, seconded by Sandy Koresch, to delegate authority to the Chairperson, to approve the Affirmative Action Order for CSB 2.91, relating to scheduling 4, 4'-Dimethylaminorex; absent the receipt of an objection to doing so within 30 days of the publication of the final order listing 4, 4'-Dimethylaminorex as a schedule I controlled substance in the federal register. Motion carried unanimously.

REPORT FROM THE REFERRAL CRITERIA WORK GROUP

MOTION: Yvonne Bellay moved, seconded by Michael Parish, to accept the recommendations of the Referral Criteria Work Group and refer the specified providers to the appropriate examining boards for further proceedings. Motion carried unanimously.

ADJOURNMENT

MOTION: Michael Parish moved, seconded by Yvonne Bellay, to adjourn the meeting. Motion carried unanimously.

The meeting adjourned at 10:10 a.m.

Virtual/Teleconference Controlled Substances Board Meeting Minutes September 10, 2021 Page 2 of 2

State of Wisconsin Department of Safety & Professional Services

1) Name and title of pers	on submitting the request:	2) Date when request submitted:		
Jon Derenne, Attorney		November 8, 2021		
bon berenne, Automey		Items will be considered late if submitted after 12:00 p.m. on the deadline		
2) Name of Deard Comm	nittee Council Costienes	date which is 8 business days before the meeting		
•	nittee, Council, Sections:			
Controlled Substances I				
4) Meeting Date:	5) Attachments:	6) How should the item be titled on the agenda page?		
November 12, 2021	⊠ Yes □ No	Revised guidance regarding the designation of gabapentin as a monitored prescription drug		
Review and consider up Gabapentin dispensing	scheduled? (If ye <u>Appearance Requ</u> Yes No nd action that should be add date to the board's Gabapen	No prescription drug 8) Is an appearance before the Board being scheduled? (If yes, please complete Appearance Request for Non-DSPS Staff) 9) Name of Case Advisor(s), if required: Yes No No No action that should be addressed: e to the board's Gabapentin guidance document to reflect that dispensers are not required to report ere the prescriber has not included their DEA number with the prescription, and may void dispensing		
11)	Α	authorization		
Jon Derenne		November 8, 2021		
Signature of person mal	king this request	Date		
Supervisor (if required)		Date		
Executive Director signa	ature (indicates approval to a	add post agenda deadline item to agenda) Date		
 Directions for including supporting documents: This form should be attached to any documents submitted to the agenda. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director. If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting. 				

AGENDA REQUEST FORM

Doug Englebert Chairperson

Alan Bloom Vice Chairperson

Yvonne M. Bellay Secretary **CONTROLLED SUBSTANCES BOARD**



4822 Madison Yards Way PO Box 8366 Madison WI 53708

Email: dsps@wisconsin.gov Voice: 608-266-2112 FAX: 608-251-3032

GUIDANCE REGARDING THE DESIGNATION OF GABAPENTIN AS A MONITORED PRESCRIPTION DRUG

Background Facts

Gabapentin is a prescription medication approved by the U.S. Food and Drug Administration for the treatment of neuropathic pain and epileptic disorders. In recent years, however, Gabapentin has been increasingly encountered by law enforcement, documented in national crime lab reports, reported to poison control centers, and diverted for illicit use. The Researched Abuse, Diversion and Addiction – Related Surveillance (RADARS) System indicates an increase in Gabapentin diversion. The Drug Abuse Warning Network (DAWN) indicates a rise in emergency department visit rates for Gabapentin.

The Wisconsin Controlled Substances Board (CSB) and the Prescription Drug Monitoring Program (PDMP) staff have received requests by health care practitioners and law enforcement to have Gabapentin included in the PDMP. Prescribers have indicated it is beneficial to be aware of a patient having a prescription for Gabapentin prior to prescribing an opioid because, when combined with opioids, there is an increased risk of respiratory depression and opioid-related mortality increases significantly. Gabapentin is sought after for illicit use due to its potentiating opioid effect.

Action Taken

In response to the facts above, the CSB has adopted Clearinghouse Rule 20-080 relating to designating Gabapentin as a prescription drug having a substantial potential for abuse, and therefore a monitored prescription drug pursuant to Wis. Stat. § 961.385 (1) (ag). Gabapentin is now listed in Wis. Admin. Code § CSB 4.03 (2) as a monitored prescription drug.

Gabapentin Has Not Been Scheduled as a Controlled Substance

Gabapentin has been designated as a monitored prescription drug, not a controlled substance. A DEA registration number is not required for a practitioner to prescribe Gabapentin, nor is a DEA registration number required for a dispenser to fill a prescription for Gabapentin.

Practical Impact for Many Prescribers and Dispensers of Gabapentin

Because Gabapentin has been designated a monitored prescription drug, a practitioner now must review a patient's prescription drug history as required by Wis. Admin. Code § CSB 4.105 prior to prescribing Gabapentin. Additionally, dispensers must report into the PDMP as required under Wis. Admin. Code § CSB 4.05 when dispensing Gabapentin.

Exemptions Where the Lack of a DEA Registration Number Causes a Dispensing Reporting Error or Prevents Practitioner Access to the PDMP

A DEA registration number is currently required information for all submissions to the PDMP. Reporting of Gabapentin without a valid prescriber or pharmacy DEA registration number will trigger a submission error and the record will not be accepted by the PDMP. As a result, a dispenser will be excused from

their duties to report Gabapentin dispensing information, and may void the dispensing record, where one of the following is true:

- The dispenser does not have a DEA registration number.
- The dispenser is attempting to report Gabapentin dispensing data where the prescribing practitioner does not have a DEA number.
- The dispenser is attempting to report Gabapentin dispensing data where the prescribing practitioner has not provided their DEA number with the prescription order.

To emphasize the third bullet point above, dispensers are <u>not</u> obligated to correct Gabapentin dispensing records where the prescriber's DEA number has been omitted from the prescription order. These Gabapentin dispensing records missing a prescriber DEA number may be voided.

Similarly, a DEA registration number is required for a practitioner to access the PDMP system. Because of this, a practitioner who does not have a DEA registration number is exempt from the general requirement to review a patient's prescription drug history report prior to prescribing Gabapentin.

Updated instructions for revising or voiding erroneous submissions of Gabapentin dispensing with missing DEA information is available in the Data Submitter Guide.

State of Wisconsin Department of Safety & Professional Services AGENDA REQUEST FORM

1) Name and title of person submitting the request: 2) Date when request submitted:					
Nilajah Hardin, Administrative Rules Coordinator				considered late if submitted after 12:00 p.m. on the deadline 8 business days before the meeting	
3) Name of Board, Com	3) Name of Board, Committee, Council, Sections:				
Controlled Substances	Board				
4) Meeting Date:	5) Attachments:			d on the agenda page? s – Discussion and Consideration	
11/12/21			nary Rule D		
	⊠ Yes □ No	a. CS	B 2.78, Rela	ting to Scheduling Crotonyl Fentanyl	
				ting to Scheduling Remimazolam ting to Scheduling Brorphine	
				Rulemaking Projects	
7) Place Item in:		nce before the Boa /es, please complete		9) Name of Case Advisor(s), if required:	
Open Session		quest for Non-DSPS		N/A	
Closed Session	☐ Yes				
	⊠ No				
10) Describe the issue a	nd action that sho	uld be addressed:			
Attachments: Preliminary Rule Dr	afts – CSB 2 78 3	79 2 81			
Rule Projects Chart	uns COD 2.70, 2	2.79, 2.01			
	Desud Desla Dusias	to Combo Wienerd	TT	/ January / Danage / Danlage Charter to a / Danage - Danlage - and	
Copies of all current	Board Rule Projec	ts Can be viewed	Here: <u>https:/</u>	/dsps.wi.gov/Pages/RulesStatutes/PendingRules.aspx	
11)		Authoriza	tion		
Mainhal	Hondin			11/02/21	
Signature of person ma	king this request			Date	
Supervisor (if required) Date					
Executive Director signature (indicates approval to add post agenda deadline item to agenda) Date					
Directions for including supporting documents:					
 This form should be attached to any documents submitted to the agenda. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director. 					
3. If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a					

meeting.

STATE OF WISCONSIN CONTROLLED SUBSTANCES BOARD

IN THE MATTER OF RULE-MAKING	:	PROPOSED ORDER OF THE
PROCEEDINGS BEFORE THE	:	CONTROLLED SUBSTANCES BOARD
CONTROLLED SUBSTANCES BOARD	:	ADOPTING RULES
	:	(CLEARINGHOUSE RULE)

PROPOSED ORDER

An order of the Controlled Substances Board to create CSB 2.78 relating to scheduling Crotonyl Fentanyl.

Analysis prepared by the Department of Safety and Professional Services.

ANALYSIS

Statutes interpreted: s. 961.16, Stats.

Statutory authority: s. 961.11 (1) and (4), Stats.

Explanation of agency authority:

Section 961.11 (1), Stats. provides that "[t]he controlled substances board shall administer this subchapter and may add substances to or delete or reschedule all substances listed in the schedules in ss. 961.14, 961.16, 961.18, 961.20 and 961.22 pursuant to the rule-making procedures of ch. 227."

Section 961.11(4), Stats. provides that "[i]f a substance is designated, rescheduled or deleted as a controlled substance under federal law and notice thereof is given to the controlled substances board, the board by affirmative action shall similarly treat the substance under this chapter after the expiration of 30 days from the date of publication in the federal register of a final order designating the substance as a controlled substance or rescheduling or deleting the substance or from the date of issuance of an order of temporary scheduling under 21 USC 811 (h), unless within that 30-day period, the board or an interested party objects to the treatment of the substance. If no objection is made, the board shall promulgate, without making the determinations or findings required by subs. (1), (1m), (1r) and (2) or s. 961.13, 961.15, 961.17, 961.19 or 961.21, a final rule, for which notice of proposed rulemaking is omitted, designating, rescheduling, temporarily scheduling or deleting the substance. If an objection is made the board shall publish notice of receipt of the objection and the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing, the board shall make a determination with respect to the treatment of the substance as provided in subs. (1), (1m), (1r) and (2) and shall publish its decision, which shall be final unless altered by statute. Upon publication of an objection to the treatment by the board, action by the board under this chapter is stayed until the board promulgates a rule under sub. (2)."

Related statute or rule: s. 961.16, Stats.

Summary of, and comparison with, existing or proposed federal regulation:

On October 2, 2020, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register listing Crotonyl Fentanyl into schedule I of the federal Controlled Substances Act. The scheduling action was effective October 2, 2020.

Plain language analysis:

This rule schedules Crotonyl Fentanyl as a Schedule I controlled substance.

The Controlled Substances Board did not receive an objection to similarly treat Crotonyl Fentanyl as a Schedule I controlled substance under ch. 961, Stats. within 30 days of the date of publication in the Federal Register of the final order designating Crotonyl Fentanyl as a controlled substance.

Pursuant to s. 961.11 (4), Stats., the Controlled Substances Board took affirmative action to similarly treat Crotonyl Fentanyl under ch. 961, Stats. by creating the following:

961.14 (2) (nd) 9m. Crotonyl Fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide).

The Affirmative Action order, dated November 13, 2020, took effect on November 23, 2020 to allow for publication in the Administrative Register and expires upon promulgation of a final rule.

Summary of public comments received on statement of scope and a description of how and to what extent those comments and feedback were taken into account in drafting the proposed rule: N/A

Comparison with rules in adjacent states:

Illinois: Illinois has not scheduled Crotonyl Fentanyl as a controlled substance.

Iowa: Iowa has not scheduled Crotonyl Fentanyl as a controlled substance.

Michigan: Michigan has not scheduled Crotonyl Fentanyl as a controlled substance.

Minnesota: Minnesota has not scheduled Crotonyl Fentanyl as a controlled substance.

Summary of factual data and analytical methodologies:

The methodology was to schedule Crotonyl Fentanyl to conform with the federal Controlled Substances Act.

Analysis and supporting documents used to determine effect on small business or in preparation of economic impact analysis:

The rule schedules Crotonyl Fentanyl as a Schedule I controlled substance which will not have any effect on small business.

Fiscal Estimate:

The proposed rules will be posted for a period of 14 days to solicit public comment on economic impact, including how the proposed rules may affect businesses, local government units, and individuals.

Effect on small business:

These proposed rules do not have an economic impact on small businesses, as defined in s. 227.114 (1), Stats. The Department's Regulatory Review Coordinator may be contacted by email at Daniel.Hereth@wisconsin.gov, or by calling (608) 267-2435.

Agency contact person:

Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, P.O. Box 8366, Madison, Wisconsin 53708; telephone 608-267-7139; email at DSPSAdminRules@wisconsin.gov.

Place where comments are to be submitted and deadline for submission:

Comments may be submitted to Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, Madison, WI 53708-8366, or by email to DSPSAdminRules@wisconsin.gov. Comments must be received by (date) to be included in the record of rulemaking proceedings.

TEXT OF RULE

SECTION 1. CSB 2.78 is created to read:

CSB 2.78 Scheduling of Crotonyl Fentanyl. Section 961.14 (2) (nd) 9m, Stats., is created to read:

961.14 (2) (nd) 9m. Crotonyl Fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide).

SECTION 2. EFFECTIVE DATE. The rules adopted in this order shall take effect on the first day of the month following publication in the Wisconsin Administrative Register, pursuant to s. 227.22 (2) (intro.), Stats.

(END OF TEXT OF RULE)

STATE OF WISCONSIN CONTROLLED SUBSTANCES BOARD

IN THE MATTER OF RULE-MAKING : PROPOSED ORDER OF THE PROCEEDINGS BEFORE THE : CONTROLLED SUBSTANCES BOARD CONTROLLED SUBSTANCES BOARD : ADOPTING RULES : (CLEARINGHOUSE RULE)

PROPOSED ORDER

An order of the Controlled Substances Board to create CSB 2.79 relating to scheduling Remimazolam.

Analysis prepared by the Department of Safety and Professional Services.

ANALYSIS

Statutes interpreted: s. 961.16, Stats.

Statutory authority: s. 961.11 (1) and (4), Stats.

Explanation of agency authority:

Section 961.11 (1), Stats. provides that "[t]he controlled substances board shall administer this subchapter and may add substances to or delete or reschedule all substances listed in the schedules in ss. 961.14, 961.16, 961.18, 961.20 and 961.22 pursuant to the rule-making procedures of ch. 227."

Section 961.11(4), Stats. provides that "[i]f a substance is designated, rescheduled or deleted as a controlled substance under federal law and notice thereof is given to the controlled substances board, the board by affirmative action shall similarly treat the substance under this chapter after the expiration of 30 days from the date of publication in the federal register of a final order designating the substance as a controlled substance or rescheduling or deleting the substance or from the date of issuance of an order of temporary scheduling under 21 USC 811 (h), unless within that 30-day period, the board or an interested party objects to the treatment of the substance. If no objection is made, the board shall promulgate, without making the determinations or findings required by subs. (1), (1m), (1r) and (2) or s. 961.13, 961.15, 961.17, 961.19 or 961.21, a final rule, for which notice of proposed rulemaking is omitted, designating, rescheduling, temporarily scheduling or deleting the substance. If an objection is made the board shall publish notice of receipt of the objection and the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing, the board shall make a determination with respect to the treatment of the substance as provided in subs. (1), (1m), (1r) and (2) and shall publish its decision, which shall be final unless altered by statute. Upon publication of an objection to the treatment by the board, action by the board under this chapter is stayed until the board promulgates a rule under sub. (2)."

Related statute or rule: s. 961.16, Stats.

Summary of, and comparison with, existing or proposed federal regulation:

On October 6, 2020, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register listing Remimazolam into schedule IV of the federal Controlled Substances Act. The scheduling action was effective October 6, 2020.

Plain language analysis:

This rule schedules Remimazolam as a Schedule IV controlled substance.

The Controlled Substances Board did not receive an objection to similarly treat Remimazolam as a Schedule IV controlled substance under ch. 961, Stats. within 30 days of the date of publication in the Federal Register of the final order designating Remimazolam as a controlled substance.

Pursuant to s. 961.11 (4), Stats., the Controlled Substances Board took affirmative action to similarly treat Remimazolam under ch. 961, Stats. by creating the following:

961.20 (2) (mo) Remimazolam.

The Affirmative Action order, dated November 13, 2020, took effect on November 23, 2020 to allow for publication in the Administrative Register and expires upon promulgation of a final rule.

Summary of public comments received on statement of scope and a description of how and to what extent those comments and feedback were taken into account in drafting the proposed rule: N/A

Comparison with rules in adjacent states:

Illinois: Illinois has not scheduled Remimazolam as a controlled substance.

Iowa: Iowa temporarily designated Remimazolam as a Schedule IV controlled substance, via their temporary amendment process, effective May 12, 2021 (<u>ARC 5541C - Iowa Administrative Rules</u>).

Michigan: Michigan has not scheduled Remimazolam as a controlled substance.

Minnesota: Minnesota has not scheduled Remimazolam as a controlled substance.

Summary of factual data and analytical methodologies:

The methodology was to schedule Remimazolam to conform with the federal Controlled Substances Act.

Analysis and supporting documents used to determine effect on small business or in preparation of economic impact analysis:

The rule schedules Remimazolam as a Schedule IV controlled substance which will not have any effect on small business.

Fiscal Estimate:

The proposed rules will be posted for a period of 14 days to solicit public comment on economic impact, including how the proposed rules may affect businesses, local government units, and individuals.

Effect on small business:

These proposed rules do not have an economic impact on small businesses, as defined in s. 227.114 (1), Stats. The Department's Regulatory Review Coordinator may be contacted by email at Daniel.Hereth@wisconsin.gov, or by calling (608) 267-2435.

Agency contact person:

Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, P.O. Box 8366, Madison, Wisconsin 53708; telephone 608-267-7139; email at DSPSAdminRules@wisconsin.gov.

Place where comments are to be submitted and deadline for submission:

Comments may be submitted to Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, Madison, WI 53708-8366, or by email to DSPSAdminRules@wisconsin.gov. Comments must be received by (date) to be included in the record of rulemaking proceedings.

TEXT OF RULE

SECTION 1. CSB 2.79 is created to read:

CSB 2.79 Scheduling of Remimazolam. Section 961.20 (2) (mo), Stats., is created to read:

961.20 (2) (mo) Remimazolam.

SECTION 2. EFFECTIVE DATE. The rules adopted in this order shall take effect on the first day of the month following publication in the Wisconsin Administrative Register, pursuant to s. 227.22 (2) (intro.), Stats.

(END OF TEXT OF RULE)

STATE OF WISCONSIN CONTROLLED SUBSTANCES BOARD

IN THE MATTER OF RULE-MAKING PROCEEDINGS BEFORE THE CONTROLLED SUBSTANCES BOARD : CONTROLLED SUBSTANCES BOARD : CLEARINGHOUSE RULE : CONTROLLED SUBSTANCES DOARD : CLEARINGHOUSE RULE : CONTROLLED SUBSTANCES DOARD : CLEARINGHOUSE RULE : CONTROLLED : CLEARINGHOUSE :

PROPOSED ORDER

An order of the Controlled Substances Board to create CSB 2.81 relating to scheduling Brorphine.

Analysis prepared by the Department of Safety and Professional Services.

ANALYSIS

Statutes interpreted: s. 961.16, Stats.

Statutory authority: s. 961.11 (1) and (4), Stats.

Explanation of agency authority:

Section 961.11 (1), Stats. provides that "[t]he controlled substances board shall administer this subchapter and may add substances to or delete or reschedule all substances listed in the schedules in ss. 961.14, 961.16, 961.18, 961.20 and 961.22 pursuant to the rule-making procedures of ch. 227."

Section 961.11(4), Stats. provides that "[i]f a substance is designated, rescheduled or deleted as a controlled substance under federal law and notice thereof is given to the controlled substances board, the board by affirmative action shall similarly treat the substance under this chapter after the expiration of 30 days from the date of publication in the federal register of a final order designating the substance as a controlled substance or rescheduling or deleting the substance or from the date of issuance of an order of temporary scheduling under 21 USC 811 (h), unless within that 30-day period, the board or an interested party objects to the treatment of the substance. If no objection is made, the board shall promulgate, without making the determinations or findings required by subs. (1), (1m), (1r) and (2) or s. 961.13, 961.15, 961.17, 961.19 or 961.21, a final rule, for which notice of proposed rulemaking is omitted, designating, rescheduling, temporarily scheduling or deleting the substance. If an objection is made the board shall publish notice of receipt of the objection and the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing, the board shall make a determination with respect to the treatment of the substance as provided in subs. (1), (1m), (1r) and (2) and shall publish its decision, which shall be final unless altered by statute. Upon publication of an objection to the treatment by the board, action by the board under this chapter is stayed until the board promulgates a rule under sub. (2)."

Related statute or rule: s. 961.16, Stats.

Summary of, and comparison with, existing or proposed federal regulation:

On March 1, 2021, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register listing Brorphine into schedule I of the federal Controlled Substances Act. The scheduling action was effective March 1, 2021.

Plain language analysis:

This rule schedules Brorphine as a Schedule I controlled substance.

The Controlled Substances Board did not receive an objection to similarly treat Brorphine as a Schedule I controlled substance under ch. 961, Stats. within 30 days of the date of publication in the Federal Register of the final order designating Brorphine as a controlled substance.

Pursuant to s. 961.11 (4), Stats., the Controlled Substances Board took affirmative action to similarly treat Brorphine under ch. 961, Stats. by creating the following:

961.14 (2) (et) Brorphine.

The Affirmative Action order, dated April 16, 2021, took effect on May 3, 2021 to allow for publication in the Administrative Register and expires upon promulgation of a final rule.

Summary of public comments received on statement of scope and a description of how and to what extent those comments and feedback were taken into account in drafting the proposed rule: $\rm N/A$

Comparison with rules in adjacent states:

Illinois: Illinois has not scheduled Brorphine as a controlled substance.

Iowa: Iowa has not scheduled Brorphine as a controlled substance.

Michigan: Michigan has not scheduled Brorphine as a controlled substance.

Minnesota: Minnesota has not scheduled Brorphine as a controlled substance.

Summary of factual data and analytical methodologies:

The methodology was to schedule Brorphine to conform with the federal Controlled Substances Act.

Analysis and supporting documents used to determine effect on small business or in preparation of economic impact analysis:

The rule schedules Brorphine as a Schedule I controlled substance which will not have any effect on small business.

Fiscal Estimate:

The proposed rules will be posted for a period of 14 days to solicit public comment on economic impact, including how the proposed rules may affect businesses, local government units, and individuals.

Effect on small business:

These proposed rules do not have an economic impact on small businesses, as defined in s. 227.114 (1), Stats. The Department's Regulatory Review Coordinator may be contacted by email at Daniel.Hereth@wisconsin.gov, or by calling (608) 267-2435.

Agency contact person:

Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, P.O. Box 8366, Madison, Wisconsin 53708; telephone 608-267-7139; email at DSPSAdminRules@wisconsin.gov.

Place where comments are to be submitted and deadline for submission:

Comments may be submitted to Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, Madison, WI 53708-8366, or by email to DSPSAdminRules@wisconsin.gov. Comments must be received by (date) to be included in the record of rulemaking proceedings.

TEXT OF RULE

SECTION 1. CSB 2.81 is created to read:

CSB 2.81 Scheduling of Brorphine. 961.14 (2) (et), Stats., is created to read:

961.14 (2) (et) Brorphine.

SECTION 2. EFFECTIVE DATE. The rules adopted in this order shall take effect on the first day of the month following publication in the Wisconsin Administrative Register, pursuant to s. 227.22 (2) (intro.), Stats.

(END OF TEXT OF RULE)

Controlled Substances Board Rule Projects (updated 11/01/21)

CH Rule Number	Scope Number	Scope Expiration Date	Code Chapter Affected	Relating Clause	Stage of Rule Process	Next Step
Not Assigned Yet	070-21	02/29/2024	CSB 2.78	Scheduling Crotonyl Fentanyl	Preliminary Rule Draft Presented at 11/12/21 Meeting	Post for EIA Comments and Submission to Clearinghouse
Not Assigned Yet	071-21	02/29/2024	CSB 2.79	Scheduling Remimazolam	Preliminary Rule Draft Presented at 11/12/21 Meeting	Post for EIA Comments and Submission to Clearinghouse
Not Assigned Yet	061-21	12/28/2023	CSB 2.80	Scheduling Oliceridine	Submission to Clearinghouse	Board Review of Final Rule Draft and Legislative Report at 01/14/22 Meeting
Not Assigned Yet	072-21	02/29/2024	CSB 2.81	Scheduling Brorphine	Preliminary Rule Draft Presented at 11/12/21 Meeting	Post for EIA Comments and Submission to Clearinghouse
Not Assigned Yet	088-21	04/18/2024	CSB 2.82	Scheduling Serdexmethylphenidate	Scope Published in Administrative Register on 10/18/21	Scope Approval for Implementation
Not Assigned Yet	089-21	04/18/2024	CSB 2.83	Scheduling 10 Fentanyl Related Substances	Scope Published in Administrative Register on 10/18/21	Scope Approval for Implementation
Not Assigned Yet	090-21	04/18/2024	CSB 2.84	Scheduling Alfaxalone	Scope Published in Administrative Register on 10/18/21	Scope Approval for Implementation
Not Assigned Yet	091-21	04/18/2024	CSB 2.85	Excluding 6-beta-Naltrexol	Scope Published in Administrative Register on 10/18/21	Scope Approval for Implementation
Not Assigned Yet	092-21	04/18/2024	CSB 2.86	Scheduling Fospropofol	Scope Published in Administrative Register on 10/18/21	Scope Approval for Implementation
Not Assigned Yet	093-21	04/18/2024	CSB 2.87	Scheduling Embutramide	Scope Published in Administrative Register on 10/18/21	Scope Approval for Implementation
Not Assigned Yet	094-21	04/18/2024	CSB 2.88	Scheduling Lacosamide	Scope Published in Administrative Register on 10/18/21	Scope Approval for Implementation

CH Rule Number	Scope Number	Scope Expiration Date	Code Chapter Affected	Relating Clause	Stage of Rule Process	Next Step
Not Assigned Yet	095-21	04/18/2024	CSB 2.89	Scheduling Perampanel	Scope Published in Administrative Register on 10/18/21	Scope Approval for Implementation
Not Assigned Yet	096-21	04/18/2024	CSB 2.90	Transferring 1- phenylcyclohexylamine and 1- piperidinocyclohexanecarbonitrile , Immediate Precursors to Phencyclidine, Also Known as PCP	Scope Published in Administrative Register on 10/18/21	Scope Approval for Implementation
Not Assigned Yet	Not Assigned Yet	Not Determined Yet	CSB 2.91	Scheduling 4,4'- Dimethylaminorex	Affirmative Action Order Published in Administrative Register on 09/27/21	Scope Statement for Board Review at 01/14/22 Meeting

State of Wisconsin Department of Safety & Professional Services

AGEND	A REQUEST FORM				
1) Name and title of person submitting the request:	2) Date when request submitted:				
Marjorie Liu	11/02/2021				
Program Lead, PDMP	Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting				
3) Name of Board, Committee, Council, Sections:					
Controlled Substances Board					
4) Meeting Date:5) Attachments:6)	How should the item be titled on the agenda page?				
	escription Drug Monitoring Program (PDMP) Updates – Discussion and onsideration				
 7) Place Item in: 8) Is an appearance is scheduled? (If yes, p Appearance Request Yes No 					
10) Describe the issue and action that should be addres	ssed:				
1. WI ePDMP Operations					
a. Q3 2021 Report					
b. Recent and Upcoming Releases					
c. Status of Grant Projects:					
i. FY 2020 Harold Rogers Pres	scription Drug Monitoring Program				
Buprenorphine Na	ïve Alert				
ii. Overdose Data Exchange Pr	roject				
iii. Buprenorphine Exclusion P	roject				
d. Interstate Data Sharing					
e. EHR Integration Status					
2. WI ePDMP Outreach					
11) Auth	norization				
Marjoris Liu	11/2/2021				
Signature of person making this request	Signature of person making this request Date				
Supervisor (if required) Date					
Executive Director signature (indicates approval to add post agenda deadline item to agenda) Date					
	mitted to the agenda. a Supervisor and the Policy Development Executive Director. bard Chairperson signature to the Bureau Assistant prior to the start of a				

2019-2021 Development and Release Summary

Updated 10.31.2021

Release Date	Description
Pending	
HRG 2020 Component 1 Release date TBD	 Security Enhancements Two-Factor Authentication Compromised Email Address Check Patient Report and other User Experience Updates
R25 November 2021	 Maintenance Updates Adjustments to triggering Annual Terms and Conditions prompt Enhanced EHR Integration Testing capabilities Chatbot display changes
Completed	
R24 August 2021	 Text Updates Gabapentin related text changes to the Submitter Error Email. Security-Related Enhancements
R23 July 2021	 Text Updates Gabapentin related text changes to the Submitter Error Email.
R22 July 2021	 Pharmacy-Related Enhancements Missing DEA Number Error Process Updates Administrative-Related Enhancements
R21 May 2021	 New Design Enhancements Proactive MC/HCP linkage renewals Search enhancements Administrative-Related Enhancements Additional administrator tools
R20 March 2021	 WI DOJ-Medical College of Wisconsin DataShare Project Automatically send data extracts to DOJ-MCW Automatically receive data extracts from DOJ-MCW Administrative-Related Enhancements Additional improvements to query process Additional administrator tools
R19 September 2020	 New Design Enhancements Enhanced MME calculation process Ability to set map display defaults Administrative-Related Enhancements

	Improvements to query approval process Search Engine Optimization
	Updates to non-user facing parts of the PDMP to optimize search engine results
R18 July 2020	 New Design Enhancements Updated layout and design of Patient Report including alerts and dispensing details, based on user feedback Opioid naïve alert Additional EHR Enhancements Multi-state default settings Prescriber Metrics Notifications Proactive notice to prescribers to review metrics, based on time and/or prescribing thresholds
R17.1 April 2020	 Pharmacy-Related Enhancements Display of Date Sold, if provided in the submission ASAP file processing improvements
R17 March 2020	 Pharmacy-Related Enhancements Improvements to workflow for error corrections/void Display of Date Sold, if provided in the submission New Design Enhancements Better access to history of recent Patient Reports for Delegates Additional data element on overdose alerts entered by law enforcement to capture administration of Naloxone MME calculator Additional EHR Enhancements Expanded patient search from within EHR Expanded navigation from within EHR
R16 Dec 2019	 Patients Panel Improvements Additional data fields EHR Enhancements Additional state query from within the EHR, as contractually allowable (initially RxCheck states only) Delegate Management ability from within EHR Ability of Delegates to identify as licensed/unlicensed
Minor Interim Release Oct 2019	 Patient matching updates Specific improvement for linking patients based on nicknames
R15.1 Sept 2019	 Performance-Related Enhancements Performance improvements for Medical Coordinator role

R15 Aug 2019	 User Management Enhancements Annual acceptance of Term and Conditions of the WI ePDMP Renewal process for Medical Coordinator access to metrics Periodic review of linked delegates
R14 April 2019	 RxCheck Technical tasks to establish connection to RxCheck interstate data sharing hub
R12 and R13 March 2019	 Data Quality Software Stability Work Technical tasks to simplify workflows and improve identification/resolution of workflow issues
R11 February 2019	 DHS Extract Addition of patient geocode latitude and longitude Quality Assurance and Support Items

Buprenorphine Naïve Alert

Consideration and advice of the Board are needed for Buprenorphine Naïve Alert that was proposed by practitioners in pain management during the BJA HR2020 focus group sessions.

Background

Buprenorphine Naïve Alert was planned in 2019 along with "Opioid Naïve Alert" to be released in 2020. Buprenorphine Naïve Alert in the end was not implemented per the advice of Dr. Westlake (then the PDMP liaison) after a discussion with two other doctors in pain management and addiction medicine. The main reason was to reduce noises that concurrent Opioid and Buprenorphine alert might create.

New circumstances have arisen as Buprenorphine for opioid use disorder will be excluded from certain calculations including the Opioid Naive Alert (scheduled to be released in Spring 2022). The focus group Buprenorphine Naive Alert proposal would only include Buprenorphine prescribed for Opioid use disorder compared to the 2019 enhancement plan that would have included any Buprenorphine. See the comparison between the two proposals below:

- 2019 Enhancement: <u>Any</u> Buprenorphine prescribed <u>since January 1, 2013</u>
- 2021 Focus Group: Buprenorphine prescribed for <u>Opioid use disorder in the past 5 years</u>

ient Histor	/ Report Resu	ilts					
RLOCK HOLM	S				Pati	ent Alerts	+ Add a Prescriber Alert
67	DOB : 01/06/1954			History of Opioids In Last 60 Days: False Latest Opioid Dispensing: 3/4/2021		3 Prescriber Al	erts 🗸
	e Latest Address: 9876 TESTINGTON WAY, , WI 53718		3718			● Law Enforcement Alerts →	
				<	0 Data-Driven A	Alerts 🗸	
rescription His	tory Locations						
-							
pioid Daily Do	se and Opioid-B	enzodiazej	pine Concurren	ce for the Past 100 Days		Bu	prenorphine Aler
							P P
ispensing His MPs are prohib	-	ulations fro	m collecting disp	pensing data from federally fi	unded opioid treatment pr	ograms.	
	-	gulations fro	m collecting disp	pensing data from federally fi	unded opioid treatment pr		efresh 🛛 💆 Export 🗸
MPs are prohib	-	gulations fro Drug Qty	m collecting disp	pensing data from federally fo			efresh ▲ Export → Patient Details
MPs are prohib	ited by federal reg	Drug			Search	C Re	

Interstate Data Sharing

RxCheck/EHR	РМРі				
In Progress					
МО					
Conn	ected				
IL, MD, NE, PA, UT, WA,	AZ, CO, DE, FL, HI, IA, ID, IN, KS, ME, MI, MN, MT, NC, ND, NM, NV, NY, PR, SC, SD, TN, WV, Military Health System				

WI ePDMP EHR Integration Services Summary

Current as of 10.31.2021
Pending Health Systems and EHR Platforms
Advanced Pain Management (In Development)
Advent Health (In Development)
Advent Health - Cerner
Athena (In Discussion)
DrFirst (In Development)
Marshfield EHR System Change (In Discussion/Contracting)
Prairie Clinic (In Discussion)
Wisconsin Statewide Health Information Network (Converting to new EHR Platform)
M Health Fairview (In Discussion/Contracting)
Bluestone Physician Services (In Discussion/Contracting)
Clean Slate (In Discussion)
Connected Health Systems (approx. 50% of monthly patient queries)
Ascension Wisconsin
Aspirus Health Care
Aurora Health Care
Children's Hospital of Wisconsin
Froedtert & the Medical College of Wisconsin
GHC of South Central Wisconsin
Gundersen Health System
HealthPartners

HSHS / Prevea Health
Marshfield Clinic
Mayo Clinic
Mercy Health
Monroe Clinic
NOVO Health Technology Group
ProHealth Care
SSM Health
Thedacare
UnityPoint
UW Health
Wisconsin Statewide Health Information Network

2021 WI PDMP Outreach Calendar

MONTH EVENT DESCRIPTION DATES NOTES January February March Rx Drug Abuse & Heroin Summit Panelist, PDMP & Patient Privacy 4/6/2021 Virtual Conference April Quarterly Meeting. Inter-agency Overdose Fatality Review (OFR) State Advisory **DSPS** Representative 4/29/2021 Group advisory group for OFR local sites. Self-Paced PDMP Training -- Lake Delton & Fox Point Police Voice-over & Animated Power Point Law Enforcement Outreach May Slides Department June PDMP Roundtable Advocate Aurora (Kenosha) 6/9/2021 Annual TTAC/BJA Regional Conference for 12 PDMPs located North Region PDMP Webinar 7/1/2021 Virtual in the PDMP TTAC North region July Law Enforcement PDMP participation promotion Collaborative Initiative between DSPS, DOJ & North Central 7/8/2021 Monthly Meeting HIDTA initiative Tribal Nation PDMP Participation MOU with St. Croix under development August September Great Lake Inter-Tribal Council Board Meeting Great Lake Inter-Tribal Council Board Meeting 9/13/2021 Family Health Center of Marshfield, Inc. PDMP Rountable 10/19/2021 October Meeting organized by National Association of Boards of In-Person or Hybrid meeting in PMP InterConnect Steering Committee Meeting 10/6-10/7/2021 Pharmacy (NABP) Northbrook, IL Comprehensive Opioid, Stimulant, and Substance Abuse Virtual conference. Required November 2021 COSSAP National Forum TBA (Initially 9/28-9/30/2021) Program (COSSAP) Annual Conference participation for BJA grantees December